PL3413870T3 - Igmezyna do zastosowania do leczenia choroby alzheimera - Google Patents
Igmezyna do zastosowania do leczenia choroby alzheimeraInfo
- Publication number
- PL3413870T3 PL3413870T3 PL17704271T PL17704271T PL3413870T3 PL 3413870 T3 PL3413870 T3 PL 3413870T3 PL 17704271 T PL17704271 T PL 17704271T PL 17704271 T PL17704271 T PL 17704271T PL 3413870 T3 PL3413870 T3 PL 3413870T3
- Authority
- PL
- Poland
- Prior art keywords
- igmesine
- alzheimer
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293832P | 2016-02-11 | 2016-02-11 | |
| EP17704271.0A EP3413870B1 (en) | 2016-02-11 | 2017-02-10 | Igmesine for use in the treatment of alzheimer's disease |
| PCT/EP2017/053066 WO2017137600A1 (en) | 2016-02-11 | 2017-02-10 | Igmesine for use in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3413870T3 true PL3413870T3 (pl) | 2022-01-10 |
Family
ID=58009847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17704271T PL3413870T3 (pl) | 2016-02-11 | 2017-02-10 | Igmezyna do zastosowania do leczenia choroby alzheimera |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11129801B2 (pl) |
| EP (2) | EP3413870B1 (pl) |
| JP (1) | JP7059192B2 (pl) |
| CN (1) | CN109069414B (pl) |
| AU (1) | AU2017218592B2 (pl) |
| CA (1) | CA3012415C (pl) |
| CY (1) | CY1124821T1 (pl) |
| DK (1) | DK3413870T3 (pl) |
| ES (1) | ES2895957T3 (pl) |
| HR (1) | HRP20211661T1 (pl) |
| HU (1) | HUE056265T2 (pl) |
| LT (1) | LT3413870T (pl) |
| PL (1) | PL3413870T3 (pl) |
| PT (1) | PT3413870T (pl) |
| RS (1) | RS62615B1 (pl) |
| SI (1) | SI3413870T1 (pl) |
| WO (1) | WO2017137600A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129801B2 (en) | 2016-02-11 | 2021-09-28 | Sigmathera Sas | Igmesine for use in the treatment of neurodegenerative diseases |
| KR20240063904A (ko) * | 2021-09-20 | 2024-05-10 | 에스테베 파마슈티칼스 에스에이 | 운동뉴런 변성 치료 또는 신경보호에 사용하기 위한 옥사디아자스피로 화합물 |
| FR3149773A1 (fr) | 2023-06-19 | 2024-12-20 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| JP7626488B1 (ja) * | 2023-10-11 | 2025-02-04 | 株式会社アイビー化粧品 | Ｍａｏ阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607824A (en) | 1983-01-11 | 1986-08-26 | Energy Absorption Systems, Inc. | Guardrail end terminal |
| FR2636625B1 (fr) * | 1988-09-01 | 1990-11-09 | Jouveinal Sa | Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| JP4600610B2 (ja) * | 1996-05-15 | 2010-12-15 | 株式会社フジモト・コーポレーション | アセチルコリン系神経伝達改善剤 |
| WO2000041684A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | A pharmaceutical combination for the treatment of depression |
| EP1078630A1 (en) | 1999-08-27 | 2001-02-28 | Warner-Lambert Company | Use of sigma receptor agonists for the treatment of depression |
| US6436938B1 (en) | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| WO2002096415A2 (en) | 2001-05-25 | 2002-12-05 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| WO2005000294A1 (en) | 2003-06-06 | 2005-01-06 | Pharmacia Corporation | Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| CN100420483C (zh) * | 2003-06-12 | 2008-09-24 | 株式会社爱慕知科学 | 用于神经元再生和功能恢复的σ配体 |
| WO2004110387A2 (en) * | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
| WO2005099823A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of alzheimers disease |
| CA2607598A1 (en) * | 2005-06-06 | 2006-12-14 | University Of South Florida | Treatment with sigma receptor agonists post-stroke |
| FR2970869B1 (fr) * | 2011-01-31 | 2013-09-06 | Centre Nat Rech Scient | Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| US11129801B2 (en) | 2016-02-11 | 2021-09-28 | Sigmathera Sas | Igmesine for use in the treatment of neurodegenerative diseases |
-
2017
- 2017-02-10 US US16/076,504 patent/US11129801B2/en active Active
- 2017-02-10 LT LTEPPCT/EP2017/053066T patent/LT3413870T/lt unknown
- 2017-02-10 AU AU2017218592A patent/AU2017218592B2/en active Active
- 2017-02-10 WO PCT/EP2017/053066 patent/WO2017137600A1/en not_active Ceased
- 2017-02-10 HU HUE17704271A patent/HUE056265T2/hu unknown
- 2017-02-10 CN CN201780021077.9A patent/CN109069414B/zh active Active
- 2017-02-10 HR HRP20211661TT patent/HRP20211661T1/hr unknown
- 2017-02-10 EP EP17704271.0A patent/EP3413870B1/en active Active
- 2017-02-10 ES ES17704271T patent/ES2895957T3/es active Active
- 2017-02-10 PT PT177042710T patent/PT3413870T/pt unknown
- 2017-02-10 SI SI201730963T patent/SI3413870T1/sl unknown
- 2017-02-10 CA CA3012415A patent/CA3012415C/en active Active
- 2017-02-10 PL PL17704271T patent/PL3413870T3/pl unknown
- 2017-02-10 EP EP21181531.1A patent/EP3903767A1/en not_active Withdrawn
- 2017-02-10 RS RS20211350A patent/RS62615B1/sr unknown
- 2017-02-10 JP JP2018543150A patent/JP7059192B2/ja active Active
- 2017-02-10 DK DK17704271.0T patent/DK3413870T3/da active
-
2021
- 2021-10-26 CY CY20211100929T patent/CY1124821T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017218592A1 (en) | 2018-08-09 |
| JP2019504872A (ja) | 2019-02-21 |
| HRP20211661T1 (hr) | 2022-02-18 |
| CA3012415C (en) | 2024-03-12 |
| PT3413870T (pt) | 2021-09-10 |
| US20190046472A1 (en) | 2019-02-14 |
| WO2017137600A1 (en) | 2017-08-17 |
| EP3413870A1 (en) | 2018-12-19 |
| DK3413870T3 (da) | 2021-11-01 |
| US11129801B2 (en) | 2021-09-28 |
| HUE056265T2 (hu) | 2022-02-28 |
| CN109069414B (zh) | 2022-01-14 |
| CY1124821T1 (el) | 2022-11-25 |
| LT3413870T (lt) | 2021-11-10 |
| ES2895957T3 (es) | 2022-02-23 |
| SI3413870T1 (sl) | 2021-12-31 |
| RS62615B1 (sr) | 2021-12-31 |
| CN109069414A (zh) | 2018-12-21 |
| CA3012415A1 (en) | 2017-08-17 |
| EP3903767A1 (en) | 2021-11-03 |
| JP7059192B2 (ja) | 2022-04-25 |
| AU2017218592B2 (en) | 2022-10-20 |
| EP3413870B1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285722A (en) | Methods for treating alzheimer's disease | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| MA45192A (fr) | Traitement d'association | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| HUE053239T2 (hu) | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére | |
| IL247085B (en) | Methods for treating Alzheimer's disease | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| ZA201605341B (en) | Methods of treating alzheimer's disease | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| IL263433A (en) | Methods for treating alzheimer's disease | |
| HUE071155T2 (hu) | Biszkolin-tetratiomolibdát Wilson-kór kezelésére | |
| LT3463351T (lt) | Parkinsono ligos gydymas | |
| PL3347002T3 (pl) | Leczenie choroby alzheimera w konkretnej populacji pacjentów | |
| PL3413870T3 (pl) | Igmezyna do zastosowania do leczenia choroby alzheimera | |
| LT3458045T (lt) | Ebselenas, skirtas naudoti menjero ligos gydymui | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
| DK3423081T3 (da) | Sammensætninger til brug i behandlingen af neurologisk sygdom | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| LT3148588T (lt) | N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui | |
| LT3164385T (lt) | N-[2-(6-fluor-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluorpropoksi)benzilamino hidrochlorido nauja polimorfinė forma, skirta alzheimerio ligos gydymui | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201614863D0 (en) | Alzheimer's disease | |
| AU2017902307A0 (en) | Treatment of alzheimer's disease | |
| AU2017902309A0 (en) | Treatment of alzheimer's disease |